Page 200 - 2021_03-Haematologica-web

R. Li et al.
specific vaccination in patients with
metastatic breast cancer. J Clin Oncol. 2009;
27(28):4685-4692.
9. Brunsvig PF, Kyte JA, Kersten C, et al.
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011;17(21):6847-6857.
10. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351-360.
11. Qian J, Wang S, Yang J, et al. Targeting heat shock proteins for immunotherapy in multi- ple myeloma: generation of myeloma-spe- cific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res. 2005;11(24 Pt 1):8808-8815.
12. Yi Q, Bergenbrant S, Osterborg A, et al. T- cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol. 1993;38(6):529-534.
13. Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T-cell acti- vation in multiple myeloma induced by M- component fragments presented by dendrit- ic cells. Br J Haematol. 1998;100(4):647-654.
14. Kim Y, Ponomarenko J, Zhu Z, et al. Immune epitope database analysis resource. Nucleic Acids Res. 2012;40(Web Server issue):W525-530.
15.Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196(2):137-151.
16. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1):77-92.
17. Alexander J, Oseroff C, Dahlberg C, et al. A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol. 2002;168(12):6189-6198.
18.Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med. 2001;194(6):833-846.
19. Qian J, Xie J, Hong S, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelo- ma. Blood. 2007;110(5):1587-1594.
20. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody- based inhibition of DKK1 suppresses tumor- induced bone resorption and multiple myeloma growth in vivo. Blood. 2007; 109(5):2106-2111.
25.Corbiere V, Chapiro J, Stroobant V, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011; 71(4):1253-1262.
22. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003; 24(2):58-61.
23. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006; 24:519-540.
24. Aarntzen EH, De Vries IJ, Lesterhuis WJ, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in den- dritic cell-based vaccination. Cancer Res. 2013;73(1):19-29.
25. Weide B, Zelba H, Derhovanessian E, et al. Functional T cells targeting NY-ESO-1 or
Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012;30(15):1835-1841.
26. Godet Y, Fabre E, Dosset M, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemother- apy response. Clin Cancer Res. 2012; 18(10):2943-2953.
27. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res. 2011;17(13):4568-4580. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration- resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
28.
29.
30.
31.
Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135(5):688-692.
Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalido- mide is an effective regimen for relapsed/refractory myeloma and is associ- ated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008;22(12):2247-2256.
Ding ZC, Zhou G. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol. 2012;2012:890178.
32.Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophos- phamide associates with longer patient sur- vival. Nat Med. 2012;18(8):1254-1261.
846
haematologica | 2021; 106(3)